Aprea Therapeutics

FDA Clearance Paves Way for Aprea Therapeutics’ Next-Gen Cancer Drug, APR-1051 to Enter Phase 1 Clinical Trial

DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) recently announced financial results for the fourth quarter and full year ended December 31, 2023. The company also provided an update on …

FDA Clearance Paves Way for Aprea Therapeutics’ Next-Gen Cancer Drug, APR-1051 to Enter Phase 1 Clinical Trial Read More